Ocumension Therapeutics (HKG:1477)
Hong Kong · Delayed Price · Currency is HKD 7.33
+0.37 (5.32%)
At close: Mar 27, 2026
Ocumension Therapeutics Revenue
In the year 2025, Ocumension Therapeutics had annual revenue of 804.35M CNY with 92.75% growth. Ocumension Therapeutics had revenue of 294.03M in the half year ending June 30, 2025, with 183.55% growth.
Revenue
804.35M CNY
Revenue Growth
+92.75%
P/S Ratio
6.68
Revenue / Employee
1.59M CNY
Employees
505
Market Cap
5.98B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 804.35M | 387.05M | 92.75% |
| Dec 31, 2024 | 417.31M | 170.94M | 69.38% |
| Dec 31, 2023 | 246.37M | 87.41M | 54.99% |
| Dec 31, 2022 | 158.96M | 102.81M | 183.11% |
| Dec 31, 2021 | 56.15M | 43.05M | 328.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.41B |
| Shanghai Haohai Biological Technology | 2.75B |
| Viva Biotech Holdings | 2.01B |
| Qyuns Therapeutics | 897.99M |
| BioDlink International Company | 831.99M |
| Shandong Boan Biotechnology | 829.27M |
| Abbisko Cayman | 681.17M |
| Alphamab Oncology | 630.11M |